Showing results (281-290 of 351) with videos related to
Sort By:
Pageof 36
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.AIDS (London, England)|July 26, 2011
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support toolAndrew D Revell, Dechao Wang, Mark A Boyd, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.Journal of Clinical Epidemiology|January 14, 2026
'Identifying Social Factors that Stratify Health Opportunities and Outcomes (ISSHOOs) in Pain Research': Explanation and elaboration to support the standardised reporting of equity-relevant dataEmma L Karran, Aidan G Cashin, Alessandro Chiarotto, et al.The Journal of Pain|December 25, 2025
Standardising socio-demographic data collection in pain research: Introducing consensus recommendations for a minimum datasetEmma L Karran, Aidan G Cashin, Alessandro Chiarotto, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.Frontiers in Immunology|June 17, 2021
Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV InfectionGerald Mak, John J Zaunders, Michelle Bailey, et al.The Journal of Infectious Diseases|December 11, 2021
A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With MenBen B Hui, Thilini N Padeniya, Nic Rebuli, et al.Journal of Viral Hepatitis|June 20, 2022
Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugsMichael W Traeger, Daniela K van Santen, Rachel Sacks-Davis, et al.The Journal of Infectious Diseases|October 17, 2006
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)Mark A Boyd, Narendra M Dixit, Umaporn Siangphoe, et al.Pageof 36